Department of Neurosurgery, University of Florida, Gainesville, Florida, USA.
J Neurointerv Surg. 2013 Nov;5(6):506-11. doi: 10.1136/neurintsurg-2012-010541. Epub 2012 Oct 6.
A number of recent trials evaluating intra-arterial therapies for acute ischemic stroke have been completed. We present a review of prospective acute ischemic stroke trials reported in a peer-reviewed forum during the last 20 years to provide insight into the general direction of this rapidly evolving field.
Prospective trials evaluating acute stroke intra-arterial therapies since 1999 were included, with the National Institute of Neurological Disorders and Stroke rtPA trial published in 1995 as a baseline comparator. Patient presenting factors and outcome data were analyzed based on year of publication and best-fit lines and linear regression analyses were generated.
Thirteen prospective trials were included. Regression analyses demonstrated no appreciable change in the median NIH Stroke Scale score of subjects at the time of enrollment since 1995 (p=0.44) and no appreciable improvements in good outcome based on a modified Rankin score of 0-2 at 90 days (p=0.66) or mortality at 90 days (p=0.55). A significant increase in time from onset of symptoms to treatment among enrolled patients was noted from 1995 to 2012 (p=0.03). In addition, a significant improvement in recanalization/reperfusion was noted over the last two decades (p=0.02).
This review of prospective acute ischemic stroke trials since 1999 indicates a substantial improvement in revascularization in the setting of a significant increase in time to therapy onset, but no appreciable change in good functional outcome.
一些评估急性缺血性脑卒中动脉内治疗的近期临床试验已经完成。我们对过去 20 年中在同行评审论坛上报告的前瞻性急性缺血性脑卒中试验进行了回顾,以深入了解这一快速发展领域的总体方向。
纳入了自 1999 年以来评估急性脑卒中动脉内治疗的前瞻性试验,并将 1995 年发表的国家神经疾病与中风研究所 tPA 试验作为基线对照。根据发表年份和最佳拟合线分析患者就诊因素和预后数据,并生成线性回归分析。
纳入了 13 项前瞻性试验。回归分析显示,自 1995 年以来,纳入患者的 NIH 卒中量表评分中位数在入组时没有明显变化(p=0.44),90 天时改良 Rankin 评分 0-2 的良好预后也没有明显改善(p=0.66)或 90 天时死亡率(p=0.55)。从症状发作到治疗的时间在纳入患者中从 1995 年到 2012 年显著增加(p=0.03)。此外,在过去二十年中,再通/再灌注显著改善(p=0.02)。
自 1999 年以来对前瞻性急性缺血性脑卒中试验的回顾表明,在治疗起始时间显著延长的情况下,再血管化有了很大的改善,但良好的功能预后没有明显变化。